Recruiting
Phase 1

LY4515100

Sponsor:

Eli Lilly and Company

Code:

NCT07867327

Conditions

Healthy

Eligibility Criteria

Sex: Male

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

[¹⁴C]-LY4515100 Oral Solution

LY4515100 Tablet

[¹⁴C]-LY4515100 IV

Study Details

Brief summary:

The main purpose of this study is to evaluate how the body handles \[¹⁴C\]-LY4515100. The study will investigate how much \[¹⁴C\]-LY4515100 enters the bloodstream from the stomach or intestines and is available to have an effect on the body, how the body changes \[¹⁴C\]-LY4515100 so that it can be used or removed, and how the body gets rid of \[¹⁴C\]-LY4515100. For each participant, the study will last about 9 weeks and will include a Clinical Research Unit (CRU) stay lasting between 10 and 30 days.

Conditions

Healthy

Study ID

NCT07867327

Start date

Oct 14, 2026

Status verified date

Nov, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18 - 55

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Are overtly healthy as determined by medical evaluation.
  • Have a body mass index (BMI) within the range of 18.0 to 35.0 kilograms per square meter (kg/m²), inclusive.

Exclusion Criteria:

  • Have significant previous or current history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinal, hematological, neurological, thromboembolism, or bleeding disorder capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study intervention; or of interfering with the interpretation of data.
  • Have a significant history of or current psychiatric disorders.
  • Have history of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs. Uncomplicated appendectomy and hernia repair will be allowed.
  • Have a history of constipation or have had acute constipation within 3 weeks prior to check-in.
  • Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing, for example, serial x-ray or computed tomography scans, barium meal, or current employment in a job requiring radiation exposure monitoring.

Study Design

Enrollment

16 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: [¹⁴C]-LY4515100 Part 1

\[¹⁴C\]-LY4515100 containing radioactivity administered orally

experimental: LY4515100 + [¹⁴C]-LY4515100 Part 2

LY4515100 administered orally with \[¹⁴C\]-LY4515100 containing radioactivity administered intravenously (IV)

Interventions

[¹⁴C]-LY4515100 Oral Solution

\[¹⁴C\]-LY4515100 administered orally

LY4515100 Tablet

LY4515100 administered orally

[¹⁴C]-LY4515100 IV

\[¹⁴C\]-LY4515100 administered IV

Primary outcome measure

  • Part 1: Urinary Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [ Time Frame: Predose Up to Day 14 ]
  • Part 1: Fecal Excretion of [¹⁴C]-LY4515100 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [ Time Frame: Predose Up to Day 14 ]
  • Part 2: Dose Normalized Ratio of the Area Under the Concentration-Time Curve After Oral Administration (AUCpo) to Area Under the Concentration-Time Curve After Intravenous Administration (AUCiv) of LY4515100 [ Time Frame: Predose Up to Day 14 ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

Fortrea Clinical Research Unit

Recruiting

Madison, Wisconsin, United States, 53704

Contacts

Principal Investigator:

Kimberly Cruz

More Information

Sponsor

Eli Lilly and Company

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.